154 related articles for article (PubMed ID: 9426066)
21. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
[TBL] [Abstract][Full Text] [Related]
22. Functional impairment of melanoma-associated p16(INK4a) mutants in melanoma cells despite retention of cyclin-dependent kinase 4 binding.
Becker TM; Rizos H; Kefford RF; Mann GJ
Clin Cancer Res; 2001 Oct; 7(10):3282-8. PubMed ID: 11595726
[TBL] [Abstract][Full Text] [Related]
23. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
Kannengiesser C; Brookes S; del Arroyo AG; Pham D; Bombled J; Barrois M; Mauffret O; Avril MF; Chompret A; Lenoir GM; Sarasin A; ; Peters G; Bressac-de Paillerets B
Hum Mutat; 2009 Apr; 30(4):564-74. PubMed ID: 19260062
[TBL] [Abstract][Full Text] [Related]
24. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
25. Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
Fujishita T; Mizushima Y; Kashii T; Kobayashi M
Anticancer Res; 1998; 18(3A):1537-42. PubMed ID: 9673367
[TBL] [Abstract][Full Text] [Related]
26. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the CDK4 gene in glioma.
Sonoda Y; Yoshimoto T; Sekiya T
Oncogene; 1995 Nov; 11(10):2145-9. PubMed ID: 7478535
[TBL] [Abstract][Full Text] [Related]
27. Novel CDKN2A mutation detected in Spanish melanoma pedigree.
de Torre C; Martínez-Escribano J
Exp Dermatol; 2010 Aug; 19(8):e333-5. PubMed ID: 20653773
[TBL] [Abstract][Full Text] [Related]
28. P16 UV mutations in human skin epithelial tumors.
Soufir N; Molès JP; Vilmer C; Moch C; Verola O; Rivet J; Tesniere A; Dubertret L; Basset-Seguin N
Oncogene; 1999 Sep; 18(39):5477-81. PubMed ID: 10498902
[TBL] [Abstract][Full Text] [Related]
29. Alterations in the regulatory pathway involving p16, pRb and cdk4 in human chondrosarcoma.
Asp J; Inerot S; Block JA; Lindahl A
J Orthop Res; 2001 Jan; 19(1):149-54. PubMed ID: 11332612
[TBL] [Abstract][Full Text] [Related]
30. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.
Yao J; Pollock RE; Lang A; Tan M; Pisters PW; Goodrich D; El-Naggar A; Yu D
Clin Cancer Res; 1998 Apr; 4(4):1065-70. PubMed ID: 9563903
[TBL] [Abstract][Full Text] [Related]
31. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.
Zuo L; Weger J; Yang Q; Goldstein AM; Tucker MA; Walker GJ; Hayward N; Dracopoli NC
Nat Genet; 1996 Jan; 12(1):97-9. PubMed ID: 8528263
[No Abstract] [Full Text] [Related]
32. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
33. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma.
Easton J; Wei T; Lahti JM; Kidd VJ
Cancer Res; 1998 Jun; 58(12):2624-32. PubMed ID: 9635589
[TBL] [Abstract][Full Text] [Related]
34. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene.
Ichimura K; Schmidt EE; Goike HM; Collins VP
Oncogene; 1996 Sep; 13(5):1065-72. PubMed ID: 8806696
[TBL] [Abstract][Full Text] [Related]
35. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi.
Papp T; Pemsel H; Zimmermann R; Bastrop R; Weiss DG; Schiffmann D
J Med Genet; 1999 Aug; 36(8):610-4. PubMed ID: 10465111
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
38. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma.
Diccianni MB; Omura-Minamisawa M; Batova A; Le T; Bridgeman L; Yu AL
Int J Cancer; 1999 Jan; 80(1):145-54. PubMed ID: 9935245
[TBL] [Abstract][Full Text] [Related]
39. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
40. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
Molven A; Grimstvedt MB; Steine SJ; Harland M; Avril MF; Hayward NK; Akslen LA
Genes Chromosomes Cancer; 2005 Sep; 44(1):10-8. PubMed ID: 15880589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
